Archive · 11 Dec 2025
Multiple IPOs Open for Subscription
Several companies in India are opening their initial public offerings (IPOs) to the public.
Nephrocare Health Services, which runs dialysis clinics, aims to raise ₹871.05 crore.
Wakefit Innovations, a mattress company, wants to raise ₹1,288.89 crore.
Park Medi World, a hospital chain, is looking to raise ₹920 crore.
Corona Remedies, a pharmaceutical company, aims to raise ₹655.37 crore.
Each IPO has different opening and closing dates, price bands, and purposes for the funds.
Analysts have mixed views on these IPOs, with some recommending them for long-term investment and others cautioning about high valuations and risks.
The companies plan to use the funds for expanding their operations, repaying debts, and other corporate purposes.
Investors are advised to consider their risk appetite and investment horizon before subscribing to these IPOs.
Nephrocare Health Services IPO opens on December 10, 2025, aiming to raise ₹871.05 crore with a price band of ₹438 to ₹460 per share.
Wakefit Innovations IPO opened on December 8, 2025, aiming to raise ₹1,288.89 crore with a price band of ₹195 per share.
Park Medi World IPO opens on December 10, 2025, aiming to raise ₹920 crore with a price band of ₹154 to ₹162 per share.
Corona Remedies IPO opened on December 8, 2025, aiming to raise ₹655.37 crore with a price band of ₹1,008 to ₹1,062 per share.
Analysts have mixed views on these IPOs, with some recommending them for long-term investment and others cautioning about high valuations and risks.
- Who
- Nephrocare Health Services, Wakefit Innovations, Park Medi World, Corona Remedies
- What
- Initial public offerings (IPOs) to raise funds for various purposes
- When
- December 2025
- Where
- India (BSE and NSE listing)
- Why
- To raise funds for expansion, debt repayment, and general corporate purposes
Positive View
Negative View
Valuation
Positive View
Analysts like SBI Securities and Anand Rathi recommend subscribing to the IPOs, citing strong growth potential, market leadership, and reasonable valuations.
Negative View
Some analysts, such as Swastika Investmart, believe certain IPOs are aggressively valued and best suited for long-term investors with a higher risk appetite.
Market Expansion
Positive View
Companies like Nephrocare and Park Medi World are expanding their operations, which is expected to boost profitability.
Negative View
Expanding and integrating new markets could introduce operational fragility and challenges in maintaining quality and oversight.
Financial Performance
Positive View
Companies like Corona Remedies have shown strong financial resilience and growth in recent years.
Negative View
High operating costs and capital-intensive models could constrain profitability for some companies.
- Nephrocare Health IPO Opening Date
- December 10, 2025
- Nephrocare Health IPO Closing Date
- December 12, 2025
- Nephrocare Health IPO Size
- ₹871.05 crore
- Nephrocare Health Price Band
- ₹438 to ₹460 per share
- Nephrocare Health Valuation (P/E)
- 69x (post-issue)
- Wakefit Innovations IPO Opening Date
- December 8, 2025
- Wakefit Innovations IPO Closing Date
- December 10, 2025
- Wakefit Innovations IPO Size
- ₹1,288.89 crore
- Wakefit Innovations Price Band
- ₹195 per share
- Park Medi World IPO Opening Date
- December 10, 2025
- Park Medi World IPO Closing Date
- December 12, 2025
- Park Medi World IPO Size
- ₹920 crore
- Park Medi World Price Band
- ₹154 to ₹162 per share
- Corona Remedies IPO Opening Date
- December 8, 2025
- Corona Remedies IPO Closing Date
- December 10, 2025
- Corona Remedies IPO Size
- ₹655.37 crore
- Corona Remedies Price Band
- ₹1,008 to ₹1,062 per share
Sources
Park Medi World IPO opens today: Should you subscribe to the ₹920 crore issue?
As NephroPlus expands abroad, scale turns into its toughest test yet
Nephrocare Health Services IPO: Analysts advise whether you should bid for the ₹871 crore issue
Corona Remedies IPO Day 3: Issue subscribed 9.96x so far. Here's GMP, subscription status - apply or not?
Wakefit Innovations IPO day 3: GMP, subscription status to review. Good or bad for investors?
Park Medi World IPO Day 1: Check GMP, subscription status, review, and more - Should you apply?
Nephrocare Health IPO Day 1 LIVE: Issue opens today; check subscription status, review, GMP, and more - Apply or not?
Park Medi World IPO opens today: Should you subscribe to this healthcare chain?
Nephrocare IPO Day 1: Issue opens today. Check GMP, review, issue details. Apply or not?
Park Medi World IPO Day 1 LIVE: Issue opens today. GMP, subscription status, review, other key details. Apply or not?
Nephrocare Health IPO off to slow start, subscribed 0.13x on opening day
